
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **September 2022**

Commission File Number: **001-36187**

EVOGENE LTD.

(Translation of Registrant's Name into English)

**13 Gad Feinstein Street, Park Rehovot, Rehovot
P.O.B 4173, Ness Ziona, 7414002, Israel**
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

[99.1](#) [Evogene Investor Presentation.](#)

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.

(Registrant)

Date: September 15, 2022

By: /s/ Yaron Eldad

Yaron Eldad

Chief Financial Officer



INVESTOR PRESENTATION

Ofer Haviv, President & CEO
September 2022

DECODING BIOLOGY

Forward Looking Statement

This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.


The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

Agenda

- ✦ **About Evogene**
- ✦ Business model
- ✦ Product-oriented subsidiaries
- ✦ Summary

Annex I - Financial Fundamentals





OUR VISION

Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies.

DECODING BIOLOGY

Life-science product development

Low probability of success with high cost and long time-to-market

Pharmaceutical
Industry



**Cost of developing a single
pharmaceutical drug**

In the 1970's

\$180 million

In recent years

>\$2 billion

Ag-chemicals
Industry




**Years to develop a new crop
protection product**

1995	2000	2005-8	2010-15
8	9	10	11+

Sources: CDER (Center for Drug Evaluation and Research), Food and Drug Administration, Tufts Center for the Study of Drug Development: <https://www.sciencedirect.com/science/article/abs/pii/S0167629616000291?via%3Dihub>
<https://www.forbes.com/sites/matthewherper/2017/10/16/the-cost-of-developing-drugs-is-insane-a-paper-that-argued-otherwise-was-insanely-bad/?sh=7533aa82d459>; Phillips McDougall, 2016; GlobeNewswire, Straight Research 2022; SpringerLink, How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment, August 2021 - <https://link.springer.com/article/10.1007/s40273-021-01065-y>; US Congressional Budget Office <https://www.cbo.gov/system/files/2021-04/57025-Rx-RnD.pdf>

Life-science product development

The ultimate case of finding “the needle in the haystack”



The challenge: Finding the winning candidates out of a **vast number of possible prospects** that address **a complex myriad of criteria**, to reach successful products



HUMAN HEALTH

AGRICULTURE

OTHER
INDUSTRIES

evogene

The opportunity

Utilizing an **advanced computational biology platform**

To identify the most promising candidates addressing multiple development challenges towards successful life-science products

- **Increase probability of success**
- **Reduce time and cost**


Biology meets disruptive technologies

CPB[★] platform

Incorporates **deep scientific understandings** together with **big data** and advanced **AI** technologies, to successfully discover & guide the **development of novel life-science based products**.

CPB[★] – Computational Predictive Biology


evogene




Tailor-made Tech Engines for product discovery & development

The CPB platform enhances product discovery and development through dedicated **Technology Engines** for products based on three core components:

- **Microbes**
- **Small molecules**
- **Genetic elements**



Example of Tech Engine User Interface




Tailor-made Tech Engines for product discovery & development

✦ Discovery

Computational selection of the most promising candidates to initiate the product development process.

✦ Development

Computational driven solution addressing optimization development challenges for the selected candidates, without impairing their ability to address other product attributes, supporting the way to **successful commercialization**.



'Ecosystem' – Potential Markets for MicroBoost AI



Building an
'Ecosystem'
around our tech
engines


Computational Biology Peer Companies

Company	 evogene <small>DECODING BIOLOGY</small>	 GINKGO BIOWORKS	 Schrödinger	 Exscientia	 RELAY <small>THERAPEUTICS</small>
Ticker	EVGN	DNA	SDGR	EXAI	RLAY


Agenda

- ✦ About Evogene
- ✦ **Business model**
- ✦ Product-oriented subsidiaries
- ✦ Summary

Annex I - Financial Fundamentals



Evogene Tech Engine – Potential Addressable Markets



Business Model

1

Product-oriented subsidiaries powered by Evogene's technology

Establish independent entities focusing on a defined commercial field with a license to use Evogene's unique solutions for product development

Subsidiaries:



Licensed to use Evogene's tech engines:



Business Model



2


Collaborations powered by Evogene's technology for the development of innovative products

Joint development with leading companies for defined products utilizing Evogene's unique solution. Typically, partner leads later-stage development and product commercialization.

Powered by Evogene's technological engines:




Evogene Tech Engine – Current Utilization



Agenda

- ✦ About Evogene
- ✦ Business model
- ✦ **Product-oriented subsidiaries**
- ✦ Summary

Annex I - Financial Fundamentals



Product-oriented subsidiaries



evogene
DECODING BIOLOGY



93%*

Microbiome based Therapeutics

- Immuno-oncology
- GI- gastrointestinal-related disorders
- AMR - Antimicrobial resistance



70%*

Ag Biologicals

- Bio-Stimulants
- Bio-Pesticides



28%

ICL \$10M SAFE investment (Aug 2022)



98%*

Ag Chemicals

- Herbicides
- Insecticides
- Fungicides



100%*

Medical Cannabis

- High yield & consumer traits
- Therapeutic traits – currently inflammation & pain



100%*

Castor Oil Production

- Yield improvement and drought tolerance
- Plant disease
- Insect control

*Evogene holdings

evogene

DECODING BIOLOGY

20

Mission:

Discovery and development of novel therapies for microbiome-related human disorders using computational biology

Product Pipeline:



Immuno-oncology program

- Combination therapy for cancer with checkpoint inhibitors
- Pre-clinical stage
- Addressable market size expected by 2026* – \$243B



GI related disorders

- Inflammatory Bowel Disorder (IBD) – pre-clinical stage
- Irritable Bowel Syndrome (IBS) – discovery stage
- Addressable market size expected by 2026: Inflammatory Bowel Disorder \$22.4B, Irritable Bowel Syndrome** \$3.3B



Antimicrobial resistance (AMR)

- Antimicrobial resistance (AMR)
- Clostridium Difficile Infection (CDI) – discovery stage
- Methicillin-resistant Staphylococcus aureus (MRSA) – discovery stage
- Addressable market size expected by 2026: CDI*** \$1.7B, MRSA**** \$3.9B

Expected main near-term value drivers:

2022

- **IBD** – initiate scale-up for GMP production of drug candidate for IBD
- **Immuno-oncology** – first data point readout from proof of concept, first in human study

2023

- **IBD** – Clinical batch production of drug candidate for IBD as preparation for Phase 1 in USA
- **Immuno-oncology** – Pre-IND Meeting with FDA

*<https://www.globenewswire.com/news-release/2019/07/17/1884118/0/en/Cancer-Immunotherapy-Market-To-Reach-USD-242-86-Billion-By-2026-Reports-And-Data.html>

**https://www.grandviewresearch.com/press-release/global-inflammatory-bowel-disease-ibd-treatment-market?utm_source=blog.goo.ne.jp&utm_medium=referral&utm_campaign=Vrushali_7Aug_hc_InflammatoryBowelDiseaseTreatmentMarket_pr&utm_content=Content

<https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market#:~:text=Report%20Overview,4.4%25%20from%202018%20to%202026..> <https://www.bloomberg.com/press-releases/2019-07-23/ibs-treatment-market-size-worth-3-3-billion-by-2026-cagr-10-1-grand-view-research-inc>

***https://www.grandviewresearch.com/press-release/global-inflammatory-bowel-disease-ibd-treatment-market?utm_source=blog.goo.ne.jp&utm_medium=referral&utm_campaign=Vrushali_7Aug_hc_InflammatoryBowelDiseaseTreatmentMarket_pr&utm_content=Content

<https://www.grandviewresearch.com/industry-analysis/inflammatory-bowel-disease-ibd-treatment-market#:~:text=Report%20Overview,4.4%25%20from%202018%20to%202026..> www.globaldata.com/global-clostridium-difficile-infections-market-approach-1-7-billion-2026/

****www.pnwswire.com/news-releases/global-methicillin-resistant-staphylococcus-aureus-mrsa-drugs-market-to-reach-over-us-39-billion-by-2025-uptake-in-the-consumption-of-antibiotics-across-the-globe-to-fuel-market-growth-observes-transparency-market-research-676949593.html

Example Results:

Immuno-Oncology program – **BMC128**
potentiate the effect of anti-PD-1 therapy
(immunotherapy) in-vivo



Improved antitumor activity in mice following the administration of BMC128, compared to treatment with immunotherapy alone

Biomica Announces Successful Enrollment of First Patient in its Phase I Study of Microbiome-Based Immuno-Oncology Drug

Proof of Concept (POC) in-human trial to take place at Rambam Health Care Campus in Israel throughout 2022

Biomica Announces First Patient Dosed in its Phase I Study of its Microbiome-Based Immuno-Oncology Drug

Mission:

Improve food quality, sustainability and agriculture productivity through microbiome based ag-biologicals technology and products

Product Pipeline:

Bio-stimulants (yield enhancement)



- Bio-stimulants 1 – focus on wheat and additional cereals. Seed treatment/soil application. Commercial stage, first sales planned in 2022. Addressable market size*: for spring wheat ±25M acres.
- Bio-stimulants 2 – focus on corn and additional crops. Seed treatment. Pre-development stage. Addressable market size*: for corn – 120M acres.

Bio-pesticides (crop protection)



- Fruit rots – focus on fruit and vegetables. Foliar application. Target market*: >\$1B of chemicals usage. Development stage 2.
- Downey Mildew – Focus on fruit and vegetables. Foliar application. Development stage 1. Target market*: >\$350M of chemicals usage.
- Seedling disease – for corn and soy. Seed treatment. pre-development stage. Target market*: >\$500M.
- Bio-insecticides – for corn and soy. Seed treatment/foliar. Pre-development stage. Target market*: >\$1.5B existing traits & chemicals market.

*Dean, R., et al. (2012). The top 10 fungal pathogens in molecular plant pathology. Molecular Plant Pathology 13:414-430 (<https://academic.oup.com/fqs/article/2/3/111/5057759>)

Expected main near-term value drivers:

2022

- **Bio-stimulants** – build infrastructure for scale-up in 'Thrivus™' sales for spring wheat in 2023
- **Fruit rot bio-fungicides** – file for regulatory approval for leading product candidate LAV.311 targeting fruit rot

2023

- **Bio-stimulants** – 'Thrivus™' product sales expansion in US and Canada for spring wheat
- **Bio-fungicides** – final preparation for filing for regulatory approval for leading product candidate LAV321 or LAV322 for downy mildew

Example Results:

- **Thrivus™** inoculant
- **LAV 311 & LAV 312** leading bio-fungicide candidates for fruit rot



Lavie Bio's wheat field in the USA during harvest –

Sales initiated in 2022



Example of treatment against *Botrytis Cinerea* vs untreated control in vines

Lavie Bio Announces Commercial Launch of its First Microbiome-Based Product for Yield Improvement – **Thrivus™**

Thrivus™ inoculant initially introduced for spring wheat in North Dakota, following positive four-year field trials

ICL and Lavie Bio Enter Strategic Collaboration to Develop Novel Bio-Stimulant Products

ICL to invest \$10 million in Lavie Bio









28%

72%



\$10M SAFE investment by ICL (Aug 2022)

Mission:

Design next-generation, effective and sustainable crop protection products by leveraging predictive biology & chemistry

Product Pipeline:

Herbicides



- Novel MoA (Mode-of-Action) selective/non-selective herbicides
- Relevant target crops – including Cereals, Rice, Corn, Soybean, Cotton, Canola, Sugar Beet, Other TBD
- Addressable market size expected by 2022*: \$34B



Insecticides

- Novel SoA (Site-of-Action) – resistance breaking
- Addressable market size expected by 2022*: \$19B

Fungicides



- Novel MoA
- Relevant target crops – including Cereals, Rice, Corn, Soybean, Cotton, Canola and Sugar Beet
- Addressable market size expected by 2025*: \$24.5B

Expected main near-term value drivers:

2022

- **New MoA Herbicide** – identify collaboration partner, finalize business terms (term sheet)
- **New MoA Herbicide** – expand data package for APTH1, AgPlenus' leading new MoA protein for the development of novel herbicides

2023

- **New MoA Herbicide** – new collaboration agreement
- **New MoA Herbicide** – phase advancement in one of the ongoing collaborations
- **New MoA Fungicide program** – initial greenhouse readouts of designed compounds on target pest
- **Platform Tools POC** – recent AgTech raises focused on platform capabilities

*<https://www.prnewswire.com/news-releases/global-3410-billion-herbicide-market-2022---research-and-markets-300458389.html>;
<https://www.marketsandmarkets.com/Market-Reports/insecticide-market-142427569.html>

Example Results:

New MoA Herbicide – **APH1**



Field test of APH1
against a panel of
grass and
broadleaf weeds –
untreated control vs
APH1



Greenhouse testing of APH1 – modified tobacco
plants with resistance trait vs unmodified control

AgPlenus Announces Reaching a 'Lead' Stage in its Novel Mode-of-Action Herbicide Program

This significant development milestone was achieved following positive results for product candidate APH1 in field tests with commercial level application rates on a broad panel of weeds

AgPlenus Announces Positive Results for a Herbicide Resistance Trait to its Leading Herbicide Product Candidate

Greenhouse proof-of-concept testing demonstrates resistance of modified model plants to AgPlenus' APH1 herbicide candidate

Mission:

Commercialize effective, precise and stable medical cannabis products, based on decoding plant genetics, for optimized therapeutic effect and patient well-being

Product Pipeline:**MetaYield⁺ Products**

High metabolite content & consumer traits



- Stable enhancement of total plant compounds focused on THC, CBD and terpenes
- Total cannabis market size expected by 2024 – \$42.7B*

Precise⁺ Products

Therapeutic traits – focus on patients' well-being



- Stable enhancement of specific active compounds to address desired effects (e.g. pain management and reduced inflammation)
- Total medical cannabis market size expected by 2024 – \$25.6B*

*Source: Arcview Market research/BDS Analytics 2020

Expected main near-term value drivers:**2022**

- **MetaYield⁺** – Commercial launch and sales of second generation products in Israel
- **Precise⁺** – Collect pre-clinical data to support commercial launch in 2023

2023

- Commercial launch and initial sales of first product in Europe
- Commercial launch of products addressing patients' well-being, such as reducing pain or inflammation

First Products: The 'G-nnovation' series

G200 inflorescence

T20/C4 Indica

Top Reported Effects

1. Pain Relief
2. Relaxation
3. Improved quality sleep
4. Muscle Relaxation



G150 inflorescence

T20/C4 Sativa

Top Reported Effects

1. Pain Relief
2. Relaxation
3. Focus
4. Uplifting



Canonic Announces Full Commercial Launch of its First Medical Cannabis Products in Israel

Canonic moves ahead of schedule with the full commercial launch of its G-nnovation products, following positive feedback from patients during the company's pre-launch campaign












Canonic Announces Positive Results in Pre-Clinical Studies in its Precise Product Program for Medical Cannabis

The results support the successful identification of specific cannabis varieties with anti-inflammatory and pain relief properties, for which Canonic recently filed a patent application

Canonic Announces Shipment of its Cannabis Varieties to Europe

Canonic is the first Israeli company shipping cannabis varieties from Israel to Europe, towards planned commercial launch in Europe in 2023

Main Subsidiaries: Industry Landscape

							
Microbiome Based Therapeutics		Ag-Biologicals		Ag-Chemicals		Medical Cannabis	
Company	Market Cap/ Funds Raised	Company	Market Cap/ Funds Raised	Company	Market Cap/ Funds Raised	Company	Market Cap/ Funds Raised
 EVELO	\$221m*	 AgBIOME	Raised \$116m* (Sep 2021)	 enKO	Raised \$70m* (July 2022)	 CRESCOLABS	\$1.1B*
 FINCH	\$124m*	 biotalys	€216m*	 moa	Raised \$44m* (Jun 2022)	 curaleaf	\$4.2B*
 SERES	\$860m*	 BIOCERES	\$860m*	 Gerthbio	Raised \$55m* (Feb 2020)	 IMC	\$34m*
 synlogic	\$77m*	 PIVOT BIO	Raised \$430m \$2.0B** rep. (July 2021)	 5Metis	Raised \$10m* (Oct 2021)	 INTERCURE	\$221m*

* Public company – market cap as of September 12, 2022 (yahoo.finance.com). Bioceres subsidiaries include Rizobacter and Marrone Bio Innovations.

Private company – amount raised in most recent financing round (crunchbase.com)


Private company - <https://www.forbes.com/sites/amyfeldman/2021/07/19/pivot-bio-nears-2-billion-valuation-as-it-raises-whopping-430-million-to-replace-synthetic-fertilizers-on-corn-and-wheat-sustainability/?sh=96ed3572273a>

The table presents valuation or amount raised in last financing round for a selected number of companies active in the same industries as our subsidiaries, is not a comprehensive list, and is presented for informational purposes only. There may be significant differences between companies active in each industry, and therefore the table does not indicate potential value for our subsidiaries, which may have no correlation to the information presented in the table and may differ significantly. Such differences may include, among others, company maturity stage, volume of sales, if any, product types, target market segments, pipeline maturity, technology, and financial position.

Agenda

- ✦ About Evogene
- ✦ Business model
- ✦ Product-oriented subsidiaries
- ✦ **Summary**

Annex I - Financial Fundamentals





144
Employees

Computational systems biology

Computational chemistry

Bioinformatics Molecular biology

Microbiology Genetics Biochemistry



28%
PhDs



56%
Women

**Incl. chairperson
of the board**

As of September 13, 2022

Summary

Revolutionizing life-science based product discovery & development, utilizing cutting edge computational biology technologies

Strong computational predictive biology (CPB) platform
leveraging synergies between a deep understanding of biology, Big Data and AI

Business ecosystem for product development around tech engines
MicroBoost AI, ChemPass AI & GeneRator AI

Computational Biology is an extremely attractive sector in its infancy with leading AI companies including Google newly involved

Dual based business model via subsidiaries or collaborations

Market-orientated subsidiaries generating value

- Biomica – Human-microbiome based therapeutics
- Lavie Bio – Ag-biologicals
- AgPlenus – Ag-chemicals
- Canonic – Medical cannabis

Significant catalysts to release value expected in the coming quatres

A hand in a purple glove holds a glowing blue ring. From the ring, numerous rays of binary code (0s and 1s) emanate, creating a digital starburst effect. The background is a gradient of purple and blue.

THANK YOU!

evogene
DECODING BIOLOGY



Annex I: Financial Fundamentals

Key Financials: Balance Sheet

Key Points:

- Consolidated cash position: ~\$35 million as of 30.06.2022, of which ~\$4 million is appropriated to Lavie Bio
- In addition, Lavie Bio received \$10M in Q3 2022 from ICL
- No bank debt
- Full year net cash burn rate, excluding exchange rate impacts in 2022, is expected to be in the range of \$26-28 million (\$18-20 million excluding Lavie Bio)
- Listed on TASE (2007) and NASDAQ (2016)

Thousands of US \$	30.06.2022	31.12.2021
Current Assets	37,705	56,890
Long-Term Assets	18,957	19,414
Total Assets	56,662	76,304
Current Liabilities	5,541	6,882
Long-Term Liabilities	5,724	6,002
Equity attributable to equity holders of the Company	36,949	53,653
Non-controlling interest	8,448	9,767
Total Liabilities & Shareholders Equity	56,662	76,304